CB Therapeutics

-10%

est. 2Y upside i

Healthcare

Fermentation-derived natural products to solve health problems

Rank

#2558

Sector

Biotechnology

Est. Liquidity

~5Y

Data Quality

Data: Low

The equity upside is highly uncertain due to missing valuation and current revenue data.

Last updated: July 19, 2026

Bull (10%)+200%

IPO or acquisition at >1.2B valuation driven by regulatory approval and TAM growth; common shares benefit after preference.

Base (50%)+20%

Exit at ~500M; preference stack consumes most proceeds, leaving modest common upside after dilution.

Bear (40%)-100%

Exit below total funding of 395M; common stock recovers nothing due to 1x preference.

Est. time to liquidity~5.0 years

Preference Stack Risk

severe

Funding Intensity

10000%

Total funding of $395M equals assumed entry valuation, giving preferred investors full claim on first $395M of exit proceeds.

Dilution Risk

moderate

Recent large round likely provides 2+ years runway, so near-term dilution risk is low; option pool expansion could add ~10%.

Secondary Liquidity

none

No secondary market activity detected; trading private shares would require company consent.

Questions to Ask at the Interview

Strategic questions based on CB Therapeutics's data — designed to show you've done your homework.

1
“What is the company's current valuation and how was it determined in the latest round?”
2
“What is the revenue run rate for 2026 and the growth trajectory?”
3
“What is the employee equity pool size and typical dilution from future rounds?”

Our model estimates -10% upside. What do you think?

Anonymous. Do not share material non-public information.

Comments are reviewed before they appear publicly.

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.